Unsuccessful CTL transfusion in a case of post-BMT Epstein-Barr virus-associated lymphoproliferative disorder (EBV-LPD)

Bone Marrow Transplantation

Volumn 20, Issue 4, 1997, Pages 337-340

  Imashuku, S ^a,b   Goto, T ^a   Matsumura, T ^a   Naya, M ^b   Yamori, M ^b   Hojo, M ^b   Hibi, S ^a   Todo, S ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO CITY HOSPITAL   (Japan)

Author keywords

Bone marrow transplantation; Cytotoxic T lymphocyte; Epstein Barr virus associated lymphoproliferative disorder

Indexed keywords

DEXAMETHASONE; ETOPOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CASE REPORT; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HUMAN; LEUKOCYTE TRANSFUSION; LYMPHOPROLIFERATIVE DISEASE; MALE; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT FAILURE;

EID: 0030842994     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700883     Document Type: Article

References (16)

1. Cladas C, Ambinder R. Epstein-Barr virus and bone marrow transplantation. Curr Opin Oncol 1995; 7: 102-106.
2. Rooney CM, Loftin SK, Holladay MS et al. Early identification of Epstein-Barr virus associated post-transplantation lymphoproliferative disease. Br J Haematol 1995; 89: 98-103.
3. Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. New Engl J Med 1994; 330: 1185-1191.
4. Heslop HE, Brenner MK, Rooney CM et al. Donor T cells as therapy for EBV lymphoproliferation post-bone marrow transplant. New Engl J Med 1994; 331: 679-680.
5. Rooney CM, Smith CA, Ng CYC et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virusrelated lymphoproliferation. Lancet 1995; 345: 9-13.
6. Gratama JW. Epstein-Barr virus infections in bone marrow transplantation recipients. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific Publications: Boston, 1994, pp 429-442.
7. Imashuku S, Iwami H, Tsunamoto K et al. Duration of Epstein-Barr virus (EBV)-associated polyclonal lymphoproliferative disease (LPD) following bone marrow transplantation. Bone Marrow Transplant 1996; 18: 823-824.
8. Shapiro RS, McClain K, Frizzera G et al. Epstein-Barr virusassociated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71: 1234-1243.
9. Trigg ME, de Alarcon P, Rumelhart S et al. Alpha-interferon therapy for lymphoproliferative disorders developing in two children following bone marrow transplants. J Biol Resp Mod 1989; 8: 603-613.
10. Zutter MM, Martin PJ, Sale GE et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520-529.
11. Lyttelton MPA, Browett PJ, Brenner MK et al. Prolonged remission of Epstein-Barr virus-associated lymphoma secondary to T cell-depleted bone marrow transplantation. Bone Marrow Transplant 1988; 3: 641-646.
12. Blanche S, Le Deist F, Veber F et al. Treatment of severe Epstein-Barr virus-induced polyclonal B lymphocyte proliferation by anti B cell monoclonal antibodies: two cases after HLA-mismatched bone marrow transplantation. Ann Intern Med 1988; 108: 199-203.
13. Craig FE. Gulley ML, Banks PM. Post-transplantation lymphoproliferative disorders. Am J Clin Pathol 1993; 99: 265-276.
14. Nalesnik MA. Post-transplantation lymphoproliferative disorders (PTLD): current perspectives. Semin Thorac Cardiovasc Surg 1996; 8: 139-148.
15. Stentoft J, Jensen MK. Terminal stage lymphoproliferative disorders treated with low-dose cytosine arabinoside. Eur J Haematol 1987: 38: 284-287.
16. Mackinnon S, Papadopoulos EB, Carabasi MH et al. Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response? Bone Marrow Transplant 1995; 15: 591-594.